Calendar

24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of March.
Here 24/7 Wall St. has included a calendar of a few of the biggest companies expecting clinical trial and FDA updates in February.
24/7 Wall St. wanted to provide a brief outlook of this last week's economic reports and some foreshadowing for the week ahead.
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
24/7 Wall St. has put together a preview of GE, Intel, Verizon and other Dow Jones Industrial Average companies due to report their quarterly results this week.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
24/7 Wall St. has collected a few more catalysts that are coming up in October for biotech and pharmaceutical companies.
24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
Some biopharma companies can see a massive upside just from winning a single mid-stage trial or even achieving as much as a Fast Track designation from the FDA.
24/7 Wall St. has collected several catalysts for biotech and pharmaceutical companies that are coming up in the first two months of 2017.
Repros Therapeutics saw its shares take a loss on Wednesday after the company provided a key FDA update.
24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of December.
This week is chock full of members of the Federal Reserve system speaking. Unfortunately, that means a whole host of dovish versus hawkish comments about interest rates.